← Leaderboards
Shujun Liu
Ohio State University
$5,854,035
Attributed
$8,510,848
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,510,848 · 5
By mechanism
R01$7,990,991 · 3
R21$364,857 · 1
R03$155,000 · 1
Top collaborators
- Gang Huang6 shared
- William W Tse4 shared
Most similar at Ohio State University
Same institution · by research overlap
- Rama K Mallampalli$45,256,042
- E Douglas Lewandowski$26,349,253
- Deliang Guo$11,121,635
- Kristin I Stanford$6,188,806
- Saame R Shaikh$6,682,858
Others in their field
Top investigators on “Link”
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- David R. Weir · University Of Michigan At Ann Arbor$206,261,870
- Clare E Reimers · Gordon Research Conferences$205,233,456
- Demian A Bailey · Oregon State University$205,233,456
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Greg Ulses · Consortium For Ocean Leadership, Inc$140,113,248
Research focus
LinkPositioning AttributeMalignant NeoplasmsLeukemiaPathway InteractionsCellsNew Therapeutic TargetInnovationGenetic TranscriptionDisease ProgressionResponseProteinsLeukemic CellIn VitroInvestigationIn VivoMediatingMolecularEpigenetic ProcessDna MethylationPre-ClinicalDesignGrowthImpairment
Grant awards (18)
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell$1,206,321
R01 · FY2025 · CA · contact PI
The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute MyelogenousLeukemia$635,657
R01 · FY2025 · CA · contact PI
The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute MyelogenousLeukemia$603,874
R01 · FY2024 · CA · contact PI
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell$573,003
R01 · FY2024 · CA · contact PI
The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute MyelogenousLeukemia$668,694
R01 · FY2023 · CA · contact PI
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell$591,097
R01 · FY2023 · CA · contact PI
The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute Myelogenous Leukemia$646,651
R01 · FY2022 · CA · contact PI
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell$618,411
R01 · FY2022 · CA · contact PI
The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute Myelogenous Leukemia$681,866
R01 · FY2021 · CA · contact PI
Targeting high fat diet-driven DNA hypermethylation for AML chemoprevention$77,500
R03 · FY2017 · CA · contact PI
Targeting high fat diet-driven DNA hypermethylation for AML chemoprevention$77,500
R03 · FY2016 · CA · contact PI
Targeting aberrant epigenetics by nanomedicine$337,895
R01 · FY2014 · CA · contact PI
Targeting aberrant epigenetics by nanomedicine$327,444
R01 · FY2013 · CA · contact PI
Targeting aberrant epigenetics by nanomedicine$361,470
R01 · FY2012 · CA · contact PI
Bioactive compound modulation of epigenetic regulator Sp1/NFkB/miR network in AML$165,844
R21 · FY2012 · CA · contact PI
Targeting aberrant epigenetics by nanomedicine$352,817
R01 · FY2011 · CA · contact PI
Bioactive compound modulation of epigenetic regulator Sp1/NFkB/miR network in AML$199,013
R21 · FY2011 · CA · contact PI
Targeting aberrant epigenetics by nanomedicine$385,791
R01 · FY2010 · CA · contact PI